The Trump Administration rescinded Executive Order 14087, which was designed to lower prescription drug costs for Medicare and Medicaid recipients. The rollback eliminated a $2 copayment cap on generic medications for Medicare beneficiaries and terminated a pilot program that helped state Medicaid programs afford expensive but life-saving cell and gene therapies. The order also removed Biden-era policies that allowed Medicare to negotiate lower drug prices for treatments granted accelerated FDA approval.